VanEck Pharmaceutical ETF
PPH
49 hedge funds and large institutions have $121M invested in VanEck Pharmaceutical ETF in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 7 closing their positions.
54% more capital invested
Capital invested by funds: $79M → $121M (+$42.4M)
7.18% more ownership
Funds ownership: 23% → 30.18% (+7.2%)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
9% less funds holding
Funds holding: 54 → 49 (-5)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$24.9M |
| 2 |
Barclays
London,
United Kingdom
|
+$15.5M |
| 3 |
Citigroup
New York
|
+$3.12M |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$3.02M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$2.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Columbia Capital
Fullerton,
California
|
-$3.25M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.09M |
| 3 |
B
Baird
Milwaukee,
Wisconsin
|
-$1.43M |
| 4 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$1.32M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
B
51
Baird
Milwaukee,
Wisconsin
| – | -$1.43M | -22,976 | Closed |
|
|
AP
52
Advisors Preferred
Rockville,
Maryland
| – | -$1.32M | -21,355 | Closed |
|
|
VKH
53
Virtu KCG Holdings
New York
| – | -$732K | -11,795 | Closed |
|
54
Northern Trust
Chicago,
Illinois
| – | -$250K | -4,030 | Closed |
|
|
HR
55
Howe & Rusling
Rochester,
New York
| – | -$6K | -100 | Closed |
|
PPH Hedge Fund Activity: Q3 2014 in Review
49 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2014, worth a combined $121M — up 54% from $79M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PPH and 2 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 16 added.
The largest buyer was Goldman Sachs, adding an estimated $24.9M. The largest seller was Columbia Capital, exiting entirely with an estimated $3.25M sold.
- 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2014, down from 54 in Q2 2014.
- Funds reported $121M of VanEck Pharmaceutical ETF stock for Q3 2014, up 54% quarter-over-quarter.
- 2 funds opened new VanEck Pharmaceutical ETF positions in Q3 2014 and 7 closed out, a net change of -5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2014 was Goldman Sachs, an estimated $24.9M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2014 was Columbia Capital, an estimated $3.25M sold.
Based on aggregated 13F filings for Q3 2014.